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Abstract 84 
 85 
Background 86 
Pre-eclampsia is a serious complication of pregnancy and contributes to maternal 87 
and offspring mortality and morbidity.  Randomised controlled trials evaluating 88 
therapeutic interventions for pre-eclampsia have reported many different outcomes 89 
and outcome measures. Such variation contributes to an inability to compare, 90 
contrast, and combine individual studies, limiting the usefulness of research to inform 91 
clinical practice. The development and use of a core outcome set would help to 92 
address these issues ensuring outcomes important to all stakeholders, including 93 
patients, will be collected and reported in a standardised fashion. 94 
 95 
Methods 96 
An international steering group including healthcare professionals, researchers, and 97 
patients, has been formed to guide the development of this core outcome set. 98 
Potential outcomes will be identified through a comprehensive literature review and 99 
semi-structured interviews with patients. Potential core outcomes will be entered into 100 
an international, multi-perspective online Delphi survey. All key stakeholders, 101 
including healthcare professionals, researchers, and patients will be invited to 102 
participate. The modified Delphi method encourages whole and stakeholder group 103 
convergence towards consensus ‘core’ outcomes.  Once core outcomes have been 104 
agreed upon it is important to determine how they should be measured. The truth, 105 
discrimination, and feasibility assessment framework will assess the quality of 106 
potential outcome measures. High quality outcome measures will be associated with 107 
core outcomes. Mechanisms exist to disseminate and implement the resulting core 108 
outcome set within an international context. 109 
 110 
Discussion 111 
Embedding the core outcome set within future clinical trials, systematic reviews, and 112 
clinical practice guidelines could make a profound contribution to advancing the 113 
usefulness of research to inform clinical practice, enhance patient care, and improve 114 
maternal and offspring outcomes.  The infrastructure created by developing a core 115 
outcome set for pre-eclampsia could be leveraged in other settings, for example 116 
selecting research priorities and clinical practice guideline development. 117 
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Prospective registration  118 
[1] Core Outcome Measures in Effectiveness Trials (COMET) registration number: 119 
588. 120 
[2] International Prospective Register of Systematic Reviews (PROSPERO) 121 
registration number: CRD42015015529. 122 
 123 
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Background 150 
Pre-eclampsia is an enigmatic pregnancy specific, multisystem syndrome 151 
characterised by reduced organ perfusion secondary to vasospasm and activation of 152 
the coagulation cascade. Despite extensive research, the cause of pre-eclampsia 153 
remains elusive. There is no international consensus regarding the diagnostic criteria 154 
for pre-eclampsia.  The International Society for the Study of Hypertension in 155 
Pregnancy (ISSHP) defines pre-eclampsia as new onset hypertension (≥140 mmHg 156 
systolic or ≥90 mmHg diastolic) developing after 20 weeks gestation presenting with 157 
new-onset proteinuria, other maternal organ dysfunction, and / or uteroplacental 158 
dysfunction.1 Pre-eclampsia is associated with maternal and offspring mortality and 159 
morbidity, especially in cases where severe features are present.2 The development 160 
of therapeutic interventions to reduce this health burden is urgently required. 161 
 162 
Selecting appropriate outcomes to reflect beneficial and harmful effects is a critical 163 
step in designing clinical studies. To ensure relevance to policy and practice the 164 
chosen outcomes need to be relevant to key stakeholders, including healthcare 165 
professionals, researchers, and patients. In the absence of a standardised approach 166 
important outcomes may not be routinely collected and reported. Even in the unlikely 167 
situation where outcomes have been consistently collected across studies, evidence 168 
synthesis can be limited by the use of different outcome measures (including 169 
definitions and instruments). For example, severe pre-eclampsia has been defined 170 
using different blood pressure thresholds, proteinuria thresholds, clinical symptoms, 171 
placental parameters, and fetal parameters.3  The development and use of a 172 
collection of well-defined, discriminatory, and feasible outcomes, termed a core 173 
outcome set, would help to address these issues.4 174 
 175 
Core outcome sets are agreed minimum sets of outcomes that can be measured in a 176 
standardised manner and reported consistently in the final publication.4  They do not 177 
necessarily need to be extensive and represent a minimum data set. Researchers 178 
remain free to measure other outcomes in addition.  We aim to replicate the success 179 
of the Outcome Measures in Rheumatology (OMERACT) initiative. This initiative has 180 
developed core outcome sets for many different conditions. Successful 181 
implementation of the rheumatoid arthritis core outcome set has resulted in a 182 
significant change in the quality and relevance of research and enriched clinical 183 
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practice by identifying consensus outcomes which are now routinely monitored by 184 
healthcare professionals and patients around the world.5 185 
 186 
A recent international initiative has developed a core outcome set for randomised 187 
trials evaluating interventions for asymptomatic preterm birth.6 One hundred and 188 
seventy-four individuals, representing five stakeholder groups, including 189 
obstetricians, midwives, neonatologists, researchers, and patients, from twenty-five 190 
countries participated in a modified Delphi method.  The method was able to reduce 191 
227 outcomes identified by a systematic review of the literature and 33 outcomes 192 
suggested by participants to 13 consensus ‘core’ outcomes.  Consensus was 193 
reached on four outcomes related to pregnant women: [1] maternal mortality; [2] 194 
maternal infection or inflammation; [3] preterm rupture of membranes; and [4] harm 195 
to mother from intervention.  Consensus was reached on nine outcomes related to 196 
the offspring: [1] gestational age at delivery; [2] offspring mortality; [3] birthweight; [4] 197 
early neurodevelopmental morbidity; [5] late neurodevelopmental morbidity; [6] 198 
gastrointestinal morbidity; [7] infectious morbidity; [8] respiratory morbidity; and [9] 199 
harm to offspring from intervention.6 200 
 201 
The objective of this study is to produce, disseminate, and implement a core 202 
outcome set for pre-eclampsia. 203 
 204 
 205 
 206 
 207 
 208 
 209 
 210 
 211 
 212 
 213 
 214 
 215 
 216 
 217 
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Methods 218 
 219 
Prospective Registration 220 
The Core Outcome Measures in Effectiveness Trials (COMET) initiative brings 221 
together researchers interested in the development, application, and promotion of 222 
core outcome sets. The study has been prospectively registered with the COMET 223 
initiative, the registration number is 588, and the International Prospective Register 224 
of Systematic Reviews (PROSPERO), the registration number is CRD42015015529. 225 
We will follow reporting guidelines for systematic reviews, as outlined by the 226 
referred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 227 
statement.7  228 
 229 
Ethical Review 230 
Approval for the qualitative patient interviews has been obtained from the National 231 
Research Ethics Service (NRES) Committee South Central ethics committee 232 
(reference number: 12/SC/0495) and all participants will be requested to provide 233 
informed written consent. The NRES has advised that the Delphi survey does not 234 
require ethical approval. 235 
 236 
Study Funding 237 
This study is funded by the National Institute for Health Research (reference: DRF-238 
2014-07-051).  The funder has no role in the design and conduct of the study, the 239 
collection, management, analysis, or interpretation of data, or manuscript 240 
preparation. 241 
 242 
Steering Group and Study Management Group 243 
An international steering group, including healthcare professionals, researchers, and 244 
patient representatives, has been formed to guide the development of this core 245 
outcome set.  Members of the steering group have been selected to represent 246 
various disciplines, geographical areas, and expertise.   Within the steering group a 247 
study management group has been established.  The study management group 248 
consists of a study coordinator (JD) and three members of the steering group (KK, 249 
RM, and SZ) who will conduct the day-to-day management of the study. 250 
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Scope of this Core Outcome Set 251 
The steering group recommended the core outcome set should apply to clinical 252 
studies evaluating therapeutic interventions for women with pre-eclampsia.  All 253 
therapeutic interventions for pre-eclampsia will be considered regardless of type, 254 
setting, or mode of administration. In order to maximise generalisability, we will not 255 
differentiate between early and late onset or mild and severe pre-eclampsia. Pre-256 
eclampsia will be defined as new onset hypertension (≥140 mmHg systolic or ≥90 257 
mmHg diastolic) after 20 weeks gestation presenting with new-onset proteinuria, 258 
other maternal organ dysfunction, or uteroplacental dysfunction.1 259 
 260 
We are not seeking to reach consensus regarding the definition of pre-eclampsia, 261 
the standardisation of other aspects of study design, or the development of a 262 
standardised database for perinatal research studies.  We acknowledge the work of 263 
the Global Pregnancy Collaboration and the International Society for the Study of 264 
Hypertension in Pregnancy (ISSHP) in these areas.1&8  We are actively collaborating 265 
with their efforts. 266 
 267 
Endorsement 268 
iHOPE is endorsed and supported by prominent national and international 269 
organisations including: [1] Action on Pre-eclampsia (APEC); [2] British Hypertension 270 
Society; [3] Core Outcomes in Women’s Health (CROWN) initiative; [4] Global 271 
Obstetrics Network (GONet); [5] Global Pregnancy Collaboration (GONet); [6] 272 
International Society for the Study of Hypertension in Pregnancy (ISSHP); [7] 273 
Obstetric Anaesthetists Association; and [8] Pre-eclampsia-Eclampsia Monitoring, 274 
Prevention and Treatment (PRE-EMPT) initiative.  275 
 276 
Study Overview 277 
The study will be divided into three distinct stages: [1] identifying potential core 278 
outcomes; [2] determining core outcomes; and [3] determining how core outcomes 279 
should be measured (figure 1). 280 
 281 
 282 
 283 
 284 
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Stage One: Identifying Potential Core Outcomes 285 
 286 
Systematic review: what outcomes have been reported before? 287 
The Cochrane Central Register of Controlled Trials (CENTRAL) is a highly 288 
concentrated source of randomised controlled trials reports (RCT) identified by 289 
searching other bibliographical databases, including EMBASE and Medline, and 290 
other sources. We will search CENTRAL to identify trials evaluating therapeutic 291 
interventions for pre-eclampsia. The screening of the records retrieved will be 292 
performed in duplicate and disagreements will be resolved by discussion. No date or 293 
language restrictions will be applied, and translations will be obtained for non-English 294 
language reports. Full text reports will be reviewed for eligible studies and data will 295 
be extracted in duplicate using a standardised and piloted data extraction proforma 296 
recording study and outcome reporting characteristics.  Disagreements will be 297 
resolved by discussion. Individual outcomes will be entered into the outcome 298 
inventory. 299 
 300 
Qualitative patient Interviews: what outcomes do patients want? 301 
Patients often identify outcomes not considered by other stakeholders or within the 302 
literature.4  Women with lived experience of pre-eclampsia will be recruited to 303 
participate in qualitative interviews through National Health Service (NHS) clinics, the 304 
patient support group Action on Pre-eclampsia, and through social media.  Potential 305 
participants will be asked to complete a recruitment questionnaire recording 306 
demographic details and information pertaining to their lived experiences of pre-307 
eclampsia. We do not intend to interview all those who volunteer, but will select 308 
participants to deliver a maximum diversity sample.  After obtaining informed 309 
consent, participants will be interviewed in a setting of their choice, usually their 310 
home.  Interview questions were developed in consultation with the steering group 311 
and guided by the literature review. The interview will start with an open-ended 312 
narrative section followed by a semi structured section with questions exploring their 313 
lived experience. The interviews will be audio or video recorded and transcribed 314 
verbatim. 315 
 316 
Data collection and analysis will be guided by a modified grounded theory approach, 317 
allowing data analysis of early interviews to enrich data collection of latter 318 
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interviews.9  These data will be analysed in consultation with a second experienced 319 
qualitative researcher using both a systematic approach of coding managed in NVivo 320 
10 (QSR International, USA) and Framework to aid contextual understanding.10 Data 321 
analysis will identify outcomes to be entered into the outcome inventory. The wording 322 
of outcomes will be grounded in the interview data and will be decided in 323 
collaboration with the patient representatives.  Data saturation will be achieved when 324 
no new substantive themes are being identified through the analysis. 325 
 326 
Outcome inventory 327 
A comprehensive inventory of outcomes identified by the systematic review and 328 
analysis of the qualitative interviews will be produced.  If there is uncertainty as to 329 
how to classify or present an outcome the advice of the steering group will be 330 
sought. Following the steering group's agreement, the outcome inventory will be 331 
entered into the modified Delphi method. 332 
 333 
Stage Two: Determining Core Outcomes  334 
Combining professional and patients’ views. 335 
The modified Delphi methods enables key stakeholders to participate in a process 336 
which assesses the extent of agreement (consensus measurement) and then 337 
resolves disagreement (consensus development).11 All key stakeholders including 338 
healthcare professionals (anaesthetists, general practitioners, obstetricians, 339 
midwives, and neonatologists), researchers, and patients will be invited to 340 
participate. There is no robust method for calculating the required sample size but 341 
typically groups have included 13 to 222 participants.11 We aim to recruit a minimum 342 
of 18 participants for each stakeholder group (anaesthetists, general practitioners, 343 
obstetricians, midwives, neonatologists, researchers, and patients) with balanced 344 
representation from high, middle, and low income countries.  Before entering the 345 
exercise participants will be allocated a unique identifier to anonymise their 346 
response. The online Delphi survey will be developed to ensure the ease of 347 
completion utilising appropriate patient terminology. Lay definitions will be available 348 
for individual outcomes. The survey will be piloted by the steering group before its 349 
use. 350 
 351 
 352 
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Round one 353 
Participants will be invited to score individual outcomes on a nine point Likert scale 354 
anchored between one (labelled ‘of limited importance for making a decision’) and 355 
nine (labelled ‘critical for making a decision’). This scale was devised by the Grading 356 
of Recommendations Assessment, Development and Evaluation (GRADE) working 357 
group to facilitate the ranking of outcomes according to their importance and has 358 
been adopted widely by core outcome set developers.12  Participants will be 359 
presented with the opportunity to add additional outcomes before completing the 360 
survey. Additional outcomes listed by participants will be reviewed and coded by the 361 
outcome committee and incorporated into round two. 362 
 363 
Round two 364 
All outcomes will be carried forward from round one into round two. For each 365 
outcome, the percentage of participants scoring individual outcomes during round 366 
one at each possible response from one to nine will be calculated and tabulated for 367 
each individual stakeholder group (healthcare professional, researchers, and 368 
patients).   Participants will be able to view the results of individual stakeholder 369 
groups.  Participants will be invited to rescore individual outcomes. The modified 370 
Delphi method promotes repeated reflection and rescoring promoting whole and 371 
stakeholder group convergence upon consensus “core” outcomes.10 372 
 373 
A standardised definition will be applied to this round’s results enabling core 374 
outcomes to be identified: 375 
[1] Consensus in (classify as a core outcome): Over 70% of participants in each 376 
stakeholder group score outcome 'critical for decision making' (score seven to nine) 377 
and less than 15% of participants in each stakeholder group score outcome 'of 378 
limited importance for decision making' (score one to three). 379 
[2] Consensus out (do not classify as a core outcome): Over 70% of participants in 380 
each stakeholder group score outcome domain 'of limited importance for decision 381 
making' (score one to three) and less than 15% of participants in each stakeholder 382 
group score outcome domain 'critical for decision making' (score seven to nine); or 383 
[3] No Consensus (do not classify as a core outcome): Anything else. 384 
 385 
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The round two results will be reviewed by the steering group to consider the need for 386 
a further Delphi survey round. 387 
 388 
Consensus meeting 389 
The results from the modified Delphi method will be considered within a consensus 390 
meeting. The meeting will include a range of views from participants that will be 391 
purposefully sampled. The objective of the consensus meeting will be to discuss 392 
outcomes not reaching consensus and approve a final core outcome set for pre-393 
eclampsia. To ensure unbiased consensus formation amongst a group of varied 394 
participants, the steering committee will ensure that the meeting is informal, 395 
inclusive, participatory and values all opinions. 396 
 397 
Stage Three: Determining How Core Outcomes Should Be Measured 398 
Ensuring outcome measures fit for purpose. 399 
Once core outcomes are agreed upon it will be important to determine how the 400 
outcomes should be defined and measured. Currently no guidelines are available to 401 
support outcome measurement instrument selection.  The Core Outcome 402 
Measurement Instrument Selection (COMIS) project is in the process of developing 403 
standard for assessing the methodological quality of studies exploring the 404 
measurement properties of instruments.13  We will assess potential instruments 405 
using the developed framework. The assessment will be undertaken in duplicate 406 
using a standardised and piloted data extraction proforma. If there is disagreement 407 
or uncertainty as to how to classify an outcome measurement the advice of the 408 
steering group will be sought. High quality outcome measures will be associated with 409 
each core outcome. The study will not advocate the use of a single outcome 410 
measure if several high quality outcome measures are identified for a single 411 
outcome. If no high quality outcome measures exist for a core outcome this will be 412 
acknowledged. 413 
 414 
 415 
 416 
 417 
 418 
 419 
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 420 
 421 
 422 
Discussion 423 
Implementing core outcome sets in future clinical studies, systematic reviews, and 424 
clinical guidelines could make a profound contribution to advancing the reach and 425 
relevance of research in informing clinical practice, enhancing patient care, and 426 
improving maternal and offspring outcomes. 427 
 428 
Improving clinical trial outcome selection. The Standard Protocol Items: 429 
Recommendations for Interventional Trials (SPIRIT) statement, supported by funders 430 
of health research, recommend the use of core outcome sets where they exist.14 A 431 
core outcome set would ensure consensus outcomes important to all stakeholders, 432 
including patients, are collected and reported. When clinical studies use consensus 433 
outcomes and outcome measures prospective meta-analysis using individual patient 434 
data is feasible. 435 
 436 
Improving clinical trial reporting and evidence synthesis.  The Core Outcomes in 437 
Women’s Health (CROWN) initiative, supported by 74 speciality journals, including 438 
the Cochrane Pregnancy and Childbirth Group, has resolved to implement core 439 
outcome sets.15 Participating journals will require authors to report the results for 440 
core outcomes within trial reports and systematic reviews and offer conclusions 441 
based on these outcomes rather than non-core or surrogate outcomes. Where core 442 
outcome sets have not been collected the authors will be asked to report this 443 
deficiency and its implications for their findings.15  444 
 445 
Improving clinical practice guidelines.  The National Institute for Health and Care 446 
Excellence (NICE) supports the use of core outcomes sets when selecting outcomes 447 
during evidence scoping and synthesis.  As this activity forms the basis of updating 448 
guideline recommendations the core outcome set could have a direct impact in 449 
influencing clinical practice.   450 
 451 
Developing infrastructure to support international collaboration. Developing a core 452 
outcome set will establish an international network of key stakeholders, including 453 
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healthcare professionals, researchers, and patients, with experience of contributing 454 
to a collaborative online study. This infrastructure could be leveraged in other 455 
settings, for example selecting research priorities and clinical practice guideline 456 
development. 457 
 458 
Conclusion 459 
Embedding the core outcome set within future clinical trials, systematic reviews, and 460 
clinical practice guidelines could make a profound contribution to advancing the 461 
usefulness of research to inform clinical practice, enhance patient care, and improve 462 
maternal and offspring outcomes.  The infrastructure created by developing a core 463 
outcome set for pre-eclampsia could be leveraged in other settings, for example 464 
selecting research priorities and clinical practice guideline development. 465 
 466 
Box 1: How do I contribute to improving pre-eclampsia research? 467 
We acknowledge the expertise and commitment of this journals’ readership to 468 
improving patient care. We warmly invite readers to participate in the modified Delphi 469 
survey by registering their interest to participate here: www.phc.ox.ac.uk/ihope 470 
 471 
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